Cancer

January 23, 2020

HDL-cholesterol and breast cancer risk

Genetic analyses suggest that high circulating HDL-cholesterol levels may increase breast cancer risk — a surprising finding since increased HDL-cholesterol is thought to be healthy.

Circulating lipids have been proposed to influence the risk of breast, colorectal and other common cancers, but results from conventional epidemiologic studies have been inconsistent.

Alicia Beeghly-Fadiel, PhD, Nikhil Khankari, PhD, Wei Zheng, MD, PhD, and colleagues in the Breast Cancer Association Consortium used Mendelian randomization analysis to evaluate associations between breast cancer risk and four genetically predicted lipid traits.

They used 162 genetic variants associated with high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), triglycerides and total cholesterol to construct weighted genetic scores for 101,424 breast cancer cases and 80,253 controls. Increased genetically predicted HDL-C was associated with an increase in breast cancer risk. Associations with triglycerides and total cholesterol were inconsistent, and no association was observed for LDL-C.

The findings, reported in the International Journal of Epidemiology, suggest that high circulating HDL-C levels may increase breast cancer risk. The authors note that the findings are surprising given that increasing HDL-C is thought to be healthy, and they point to the need for additional research.

This research was supported by the National Institutes of Health (grants CA070867, CA160056) and endowment funds for the Ingram Professorship and Anne Potter Wilson Chair at Vanderbilt University. The Breast Cancer Association Consortium is funded by Cancer Research UK and by the European Community’s Seventh Framework Programme.